Approximately 70 million people currently live with epilepsy worldwide [1]. The availability and accessibility of antiepileptic drugs has been an issue for developing countries. In Asia, the treatment gap has ranged from 28% to as high as 98% [2]. For those who received antiepileptic drugs, there were about one-third of patients who still continue to have seizures [3]. Patients with drug-resistant epilepsy are potential candidates for surgery especially those with surgically remediable syndrome, such as mesial temporal sclerosis or focal cortical dysplasia.
7
ABR
ABR
0